Remove 2024 Remove Molecular Biology Remove Regulations
article thumbnail

Machine learning guides researchers to new synthetic genetic switches

Broad Institute

Machine learning guides researchers to new synthetic genetic switches By Tom Ulrich October 23, 2024 Breadcrumb Home Machine learning guides researchers to new synthetic genetic switches A new method allows precise activation or repression of genes in specific cells and tissues. Online October 23, 2024. By Sarah C.P.

Research 136
article thumbnail

My Attendance at the 2024 Boston Society Cell and Gene Therapy Conference

Alta Sciences

My Attendance at the 2024 Boston Society Cell and Gene Therapy Conference pmjackson Tue, 06/11/2024 - 20:49 , via Wikimedia Commons" data-entity-type="file" data-entity-uuid="c7a7fa8b-b2fe-4d84-a75e-d1ba3a4e2caf" src="[link] width="742" height="249" loading="lazy" /> Ecm85, CC BY-SA 3.0 Tags Bioanalysis Weight 16

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The essential role of recombinant phage display antibody libraries

Drug Target Review

In 2024 alone, almost 50 antibody drug candidates are anticipated to enter regulatory review, the majority of which are mAbs. 3 This change signals a major shift away from animal use in drug safety regulation and encourages the use of alternative methods like organ-on-chip or other animal-free technologies. Antibodies to watch in 2024.

article thumbnail

Mediating BRAF-mutant melanoma resistance

Drug Target Review

Our data demonstrate that the CoREST complex is a critical mediator of the distinct melanoma phenotypes, working through the regulation of both the phenotype-defining genes MITF and AXL as well as the master regulators of epithelial-to-mesenchymal transitions (EMT) and phenotype switching in melanoma and other cancers, SNAIL/SLUG/ZEB1/ZEB2.

article thumbnail

SRP-001: redefining pain treatment with a safer, non-opioid analgesic

Drug Target Review

SRP-001 targets the central nervous system (CNS) by producing N-arachidonoylaminophenol (AM404) in the midbrain’s periaqueductal grey (PAG) region, crucial for pain sensation and regulation. Scientific Reports 14, 11103 (2024). He was bestowed the 2024 NIH HEAL Director’s Trailblazer Award for this work.

article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

Dr Rochlin earned a PhD in Molecular Biology and Genetics from Weill Cornell Medical College, conducting research at Sloan Kettering Institute, and a BA in Biology from the University of Pennsylvania. Regulation of cutaneous malignancy by gammadelta T cells. Nat Cancer (2024 January 3).

Therapies 105
article thumbnail

Alzheimer’s disease: driving advancements with precision medicine

Drug Target Review

2024, July 28). Progress in molecular biology and translational science. Alzheimer’s Association International Conference; 2024 July 28 – August 1; Philadelphia, PA. 2024, January 19). Α-synuclein in the pathophysiology of alzheimer’s disease – molecular neurodegeneration. link] Yifei Lu, P.

Disease 59